APO-SALVENT 5MG/ML SOLUTION

Valsts: Kanāda

Valoda: angļu

Klimata pārmaiņas: Health Canada

Aktīvā sastāvdaļa:

SALBUTAMOL (SALBUTAMOL SULFATE)

Pieejams no:

APOTEX INC

ATĶ kods:

R03AC02

SNN (starptautisko nepatentēto nosaukumu):

SALBUTAMOL

Deva:

5MG

Zāļu forma:

SOLUTION

Kompozīcija:

SALBUTAMOL (SALBUTAMOL SULFATE) 5MG

Ievadīšanas:

INHALATION

Vienības iepakojumā:

10ML

Receptes veids:

Prescription

Ārstniecības joma:

SELECTIVE BETA 2-ADRENERGIC AGONISTS

Produktu pārskats:

Active ingredient group (AIG) number: 0108887006; AHFS:

Autorizācija statuss:

APPROVED

Autorizācija datums:

1993-08-11

Produkta apraksts

_Page 1 of 32_
PRODUCT MONOGRAPH
PR
APO-SALVENT RESPIRATOR SOLUTIONS
(SALBUTAMOL SULFATE SOLUTIONS BP)
PR
APO-SALVENT RESPIRATOR SOLUTION 50 MG IN 10 ML (5 MG/ML SALBUTAMOL)
PR
APO-SALVENT STERULES 1.25 MG IN 2.5 ML (0.5 MG/ML SALBUTAMOL)
PR
APO-SALVENT STERULES 2.5 MG IN 2.5 ML (1 MG/ML SALBUTAMOL)
PR
APO-SALVENT STERULES 5.0 MG IN 2.5 ML (2 MG/ML SALBUTAMOL)
BRONCHODILATOR,
Β
2
-ADRENERGIC STIMULANT
APOTEX INC.
150 SIGNET DRIVE
TORONTO, ONTARIO
DATE OF REVISION:
M9L 1T9
March 16, 2020
CONTROL # 236795
_Page 2 of 32_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................................................
3
SUMMARY PRODUCT INFORMATION
..................................................................................................................
3
INDICATIONS AND CLINICAL USE
........................................................................................................................
3
CONTRAINDICATIONS
.............................................................................................................................................
3
WARNINGS AND PRECAUTIONS
............................................................................................................................
4
ADVERSE REACTIONS
.............................................................................................................................................
7
DRUG INTERACTIONS
..............................................................................................................................................
8
DOSAGE AND ADMINISTRATION
........................................................................................................................
10
OVERDOSAGE
..........................................................................................................................................................
12
ACTION AND CLINICAL PHARMACOLOGY
......................................................................................